Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial
- 1 May 2006
- journal article
- research article
- Published by BMJ in International Journal of Gynecologic Cancer
- Vol. 16 (3), 1075-1081
- https://doi.org/10.1111/j.1525-1438.2006.00598.x
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Epitope specificity and longevity of a vaccine-induced human T cell response against HPV18International Immunology, 2004
- Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7)Vaccine, 2004
- Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccineVaccine, 2002
- Immune evasion in human papillomavirus-associated cervical cancerNature Reviews Cancer, 2002
- A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cellNature, 1998
- T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactionsNature, 1998
- Large clonal expansions of CD8+ T cells in acute infectious mononucleosisNature Medicine, 1996
- A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancerThe Lancet, 1996
- Tumor Antigens Recognized by T LymphocytesAnnual Review of Immunology, 1994
- Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7Virology, 1991